venglustat; ibiglustat
Jump to navigation
Jump to search
Contraindications
- treatment of GBA1-associated Parkinson's disease
Mechanism of action
- brain-penetrant glucosylceramide synthase inhibitor
More general terms
References
- ↑ Giladi N et al. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: An international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2023 Aug; 22:661. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37479372 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00205-3/fulltext
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60199242
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=91618134
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=91618117
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60199241
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=78425810